19 April 2021 – Bioserve Biotechnologies India Pvt. Ltd. launches clinical oncology diagnostic services in India.

19 April 2021
Clinical Capabilities

Hyderabad India – 19 April 2021: Bioserve Biotechnologies India Pvt Ltd, a 100% owned subsidiary of REPROCELL Inc, is pleased to announce the launch of clinical oncology diagnostic service in India. This new service is clinician-friendly, aiming to deliver comprehensive, NGS-based genomic profiling in oncology targeting a wide range of cancers. The company also provides pharmacogenomics testing using single gene panels, offering researchers detailed interpretations and recommendations that provide powerful insights for the development of targeted therapies.

Rama Modali, CEO of Bioserve Biotechnologies India Pvt Ltd mentioned, “Through our clinical diagnostic service portfolio, Bioserve is proud to support patients, clinicians and other experts by providing tools for better diagnose various cancer types, as well as to provide support to better strategize cancer treatment approaches.”

For more information, please contact bioserve.india@reprocell.com, or visit the company website at https://bioserve.in/

About Bioserve Biotechnologies India Pvt. Ltd: Bioserve Biotechnologies India Pvt. Ltd. has been REPROCELL’s subsidiary since April 2018. Since its inception in 2002, the company has been the prime resource for primer synthesis, DNA sequencing related services, utilizing the Sanger platforms, next generation sequencing services and bioinformatics services for many of the top life science industries, research organizations and academic research institutions across India covering more than 6000 customers.


07AUG20 cancer cell metastisis

 

Stay informed

Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).